---
title: FidoCure Leads Canine Cancer Research with the World’s Largest Canine Cancer Database
description: FidoCure is leading the way in canine cancer research with genomic sequencing, AI, and real-world data from dogs with naturally occurring cancers.
image: https://blog.fidocure.com/hubfs/Blog_Database.png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# FidoCure Leads Canine Cancer Research with the World’s Largest Canine Cancer Database
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/fidocure-leads-canine-cancer-research-with-the-worlds-largest-canine-cancer-database) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/fidocure-leads-canine-cancer-research-with-the-worlds-largest-canine-cancer-database) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/fidocure-leads-canine-cancer-research-with-the-worlds-largest-canine-cancer-database)
At FidoCure, we're committed to transforming cancer care for dogs through precision medicine. Our journey began with a mission to address a critical gap in canine cancer research and treatment. Prior to 2019, the field of canine cancer genomics lagged significantly behind its human counterpart. With only 2,000 canine tumor samples sequenced worldwide (compared to 20,000 human samples), the potential for precision medicine in veterinary oncology remained largely untapped.
Recognizing this unmet need, FidoCure set out to build the world's largest dataset of canine cancer genomics. Our efforts have led to remarkable progress. In 2023, we published a [study](https://doi.org/10.1038/s41598-023-37505-2)detailing the genomic sequencing of 671 naturally occurring canine tumors. This study not only expanded our understanding of canine cancer but also positioned dogs as a valuable translational model for human cancer research. Our innovative approach ensures that each dog enrolled in our program benefits from the collective knowledge gained from all previous participants.
Building on this initial success, FidoCure has rapidly expanded its reach and impact. A 2023 study published in [*Nature Precision Oncology*](https://doi.org/10.1038/s41698-023-00346-3) utilized our platform to enroll 2,119 dogs with cancer, further demonstrating the potential of our approach. Today, the FidoCure platform includes data from over 5,000 dogs, reflecting our commitment to transforming cancer care for our canine companions.
FidoCure's precision medicine approach leverages advanced genomic sequencing and real-world data from dogs with naturally occurring cancers. This empowers pet owners and veterinarians with crucial insights for making informed treatment decisions. We identify specific genetic mutations driving each patient's cancer, which may benefit from small-molecule targeted drugs. Our personalized solutions can lead to better outcomes, fewer side effects, and improved quality of life for dogs. Moreover, we analyze vast amounts of genomic, clinical, and environmental data to uncover patterns and insights that inform more effective, tailored treatment strategies.
FidoCure has successfully brought canine cancer genomic sequencing out of the lab and into real-world clinical settings. Our advanced tools allow veterinary partners to identify the specific genetic alterations underlying a pet's cancer, select targeted therapies to disrupt cancer pathways effectively, and continuously improve treatment strategies based on ongoing data analysis.
By studying real-world cases, FidoCure is paving the way for more effective and targeted therapies, accelerating the development of precision oncology treatments for canine cancer, and contributing to the broader field of oncology, potentially benefiting both canine and human patients. As we continue to expand our dataset, the promise of more personalized and effective cancer care for dogs grows stronger. At FidoCure, we're committed to a future where every dog with cancer has access to the most advanced, tailored treatments available.
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/delivering-difficult-news-how-to-talk-to-pet-parents-about-canine-cancer)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
### [Delivering Difficult News: How to Talk to Pet Parents About Canine Cancer](https://blog.fidocure.com/fidocure-blog/delivering-difficult-news-how-to-talk-to-pet-parents-about-canine-cancer)
#### As veterinarians, our work involves a wide range of emotions. We may experience the joy of treating a sick pet and seeing them recover, but we may also have to deliver...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/delivering-difficult-news-how-to-talk-to-pet-parents-about-canine-cancer)
[](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
### [FidoCure CEO Christina Lopes to Showcase World's First Portfolio of Canine Cancer Drugs at 2024 Animal Health Summit](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
FidoCure CEO Christina Lopes will present at the 2024 Animal Health Summit in Kansas City on August 26-27. The summit will showcase emerging companies and foster...
[Christina K. Lopes](https://blog.fidocure.com/fidocure-blog/author/christina-k-lopes)
[Read More](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "FidoCure",
"url" : "https://blog.fidocure.com/fidocure-blog/author/fidocure"
},
"dateModified" : "2024-09-24T13:00:04.541Z",
"datePublished" : "2024-09-24T13:00:00.000Z",
"headline" : "FidoCure Leads Canine Cancer Research with the World’s Largest Canine Cancer Database",
"image" : [ "https://blog.fidocure.com/hubfs/Blog_Database.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/fidocure-leads-canine-cancer-research-with-the-worlds-largest-canine-cancer-database",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```